Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

You searched for id:"oai:researchspace.ukzn.ac.za:10413/18515". One record found.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


University of KwaZulu-Natal

1. De Jager, Hendrik Petrus. The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa.

Degree: 2017, University of KwaZulu-Natal

Rationale for the study The growth of pharmaceutical expenditure as a percentage of total health care expenditure has stagnated, both locally and globally, despite increasing consumption. Two factors that contributed to the stagnation are the introduction of generic medicines after patent expiry, and the introduction of cost-containment policies, like generic reference pricing. The introduction of generic medicines offer the opportunity to reduce medicine expenditure because of a switch in utilisation from expensive brand-name originator products to more cost-effective generic alternatives. Reference pricing is a policy where therapeutically similar medicines are grouped together, and a maximum reimbursement rate is set for the group. If a patient chooses to use a product more expensive than the reference price, they have to pay the difference in price. In the South African context, generically similar products are grouped together and the reimbursement rate is set at the average price of the generically equivalent products. Aims and objectives The aim of the study is to determine the impact of the introduction of generics and generic reference pricing on two active ingredients, candesartan and rosuvastatin, which recently lost their patent protection, in the South African private health care sector, for the period January 2012 to December 2015. To achieve this aim, three objectives were identified: 1. To measure the impact on medicine utilisation after the introduction of generics and generic reference pricing on candesartan and rosuvastatin. 2. To measure the impact on the average medicine price after the introduction of generics and generic reference pricing on candesartan and rosuvastatin. 3. To measure the impact on medicine expenditure after the introduction of generics and generic reference pricing on candesartan and rosuvastatin. Method Medicine claims for candesartan and rosuvastatin was obtained from a Pharmacy Benefit Manager in South Africa. The claims covered a 48-month period from January 2012 to December 2015 and provided a pre- and post-reference price period for analysis. Medicine utilisation was measured as the number of Defined Daily Doses dispensed per 100 000 beneficiaries. Medicine price and expenditure was calculated as the average per Defined Daily Dose. Results Candesartan experienced an average 7.0% year-on-year decline in utilisation and rosuvastatin a 5.0% increase. Utilisation of generic medicines was 59.3% of the total volume in the final year of the study for candesartan and 76.4% for rosuvastatin. The introduction of generic alternatives resulted in a 31.0% reduction in the average price per Defined Daily Dose for candesartan and a 13.9% reduction for rosuvastatin. Medicine expenditure reduced by an additional 34.6% and 20.9% for candesartan and rosuvastatin respectively, because of the introduction of generic reference pricing. The total saving because of the introduction of generics and generic reference pricing was 54.8% for… Advisors/Committee Members: Suleman, Fatima. (advisor).

Subjects/Keywords: Generic medicines.; Candesartan.; Rosuvastatin.; Pharmaceutical expenditure.; Health care sector.

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

De Jager, H. P. (2017). The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa. (Thesis). University of KwaZulu-Natal. Retrieved from https://researchspace.ukzn.ac.za/handle/10413/18515

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

De Jager, Hendrik Petrus. “The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa.” 2017. Thesis, University of KwaZulu-Natal. Accessed July 08, 2020. https://researchspace.ukzn.ac.za/handle/10413/18515.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

De Jager, Hendrik Petrus. “The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa.” 2017. Web. 08 Jul 2020.

Vancouver:

De Jager HP. The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa. [Internet] [Thesis]. University of KwaZulu-Natal; 2017. [cited 2020 Jul 08]. Available from: https://researchspace.ukzn.ac.za/handle/10413/18515.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

De Jager HP. The impact of the introduction of generics and generic references pricing and candesartan and rosuvastatin utilisation, price and expenditure in South Africa. [Thesis]. University of KwaZulu-Natal; 2017. Available from: https://researchspace.ukzn.ac.za/handle/10413/18515

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

.